Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (932)	10/16/1998 8:41:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Merck's 3rd-Quarter Net Rises 14%, Fueled by Sales of Zocor Bloomberg News October 16, 1998, 7:50 a.m. ET Merck's 3rd-Quarter Net Rises 14%, Fueled by Sales of Zocor Whitehouse Station, New Jersey, Oct. 16 (Bloomberg) -- Merck & Co., the world's largest drugmaker, said third-quarter net income rose 14 percent as it introduced five new drugs, including its once-a-day asthma medicine Singulair and Propecia, a pill to fight baldness. Net income rose to $1.37 billion, or $1.12 a share, from $1.20 billion, or 97 cents, a year earlier. Sales rose 15 percent to $6.84 billion from $5.93 billion. Merck was expected to earn $1.11 a share, the average estimate of analysts polled by First Call Corp. In the third quarter, Merck had $990 million in sales of the cholesterol reducer Zocor. --Kerry Dooley in the Princeton newsroom (609) 279-4016